Search research articles
Contact Us
Filters
Showing results (101-110 of 172) with videos related to
Page
of 18
Sort By:
Journal of Chemotherapy (Florence, Italy)
|
June 11, 2015
Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin
Rodrigo E Mendes, Robert K Flamm, David J Farrell, et al.
International Journal of Antimicrobial Agents
|
September 8, 2005
Evaluation of telithromycin against Streptococcus pneumoniae with ribosomal mutations utilizing in vitro time-kill methodology
Prachi K Dandekar, Pamela R Tessier, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy
|
June 30, 2016
Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014
Michael A Pfaller, Robert K Flamm, Ronald N Jones, et al.
The Journal of Antimicrobial Chemotherapy
|
November 3, 2014
Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13)
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy
|
April 20, 2011
Genetic resistance elements carrying mef subclasses other than mef(A) in Streptococcus pyogenes
Maria Del Grosso, Romina Camilli, Giada Barbabella, et al.
Antimicrobial Agents and Chemotherapy
|
December 21, 2011
Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010
Rodrigo E Mendes, Leah N Woosley, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy
|
March 23, 2016
Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Journal of Clinical Microbiology
|
March 25, 2016
Comparison of BD Max StaphSR and BD Max MRSAXT for Screening of Staphylococcus aureus Clinical Isolates Collected from Hospitals in the United States
Rodrigo E Mendes, Amy A Watters, Paul R Rhomberg, et al.
Antimicrobial Agents and Chemotherapy
|
October 29, 2014
Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
November 25, 2010
Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program
Douglas J Biedenbach, David J Farrell, Rodrigo E Mendes, et al.
Page
of 18
Search research articles
Search
Showing results (101-110 of 172) with videos related to
Sort By:
Page
of 18
Journal of Chemotherapy (Florence, Italy)
|
June 11, 2015
Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin
Rodrigo E Mendes, Robert K Flamm, David J Farrell, et al.
International Journal of Antimicrobial Agents
|
September 8, 2005
Evaluation of telithromycin against Streptococcus pneumoniae with ribosomal mutations utilizing in vitro time-kill methodology
Prachi K Dandekar, Pamela R Tessier, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy
|
June 30, 2016
Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014
Michael A Pfaller, Robert K Flamm, Ronald N Jones, et al.
The Journal of Antimicrobial Chemotherapy
|
November 3, 2014
Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13)
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy
|
April 20, 2011
Genetic resistance elements carrying mef subclasses other than mef(A) in Streptococcus pyogenes
Maria Del Grosso, Romina Camilli, Giada Barbabella, et al.
Antimicrobial Agents and Chemotherapy
|
December 21, 2011
Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010
Rodrigo E Mendes, Leah N Woosley, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy
|
March 23, 2016
Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Journal of Clinical Microbiology
|
March 25, 2016
Comparison of BD Max StaphSR and BD Max MRSAXT for Screening of Staphylococcus aureus Clinical Isolates Collected from Hospitals in the United States
Rodrigo E Mendes, Amy A Watters, Paul R Rhomberg, et al.
Antimicrobial Agents and Chemotherapy
|
October 29, 2014
Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
November 25, 2010
Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program
Douglas J Biedenbach, David J Farrell, Rodrigo E Mendes, et al.
Page
of 18